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Adriamycin and mitomycin C were reduced by xanthine oxidase/NADH in the presence of a DNA template comprising 
a stable initiated ternary transcription complex derived from the lac UV5 promoter. Subsequent elongation of the tran- 
scription complex treated with mitomycin C revealed high levels of terminated transcripts one nucleotide prior to G resi- 
dues on the coding strand (i.e. at X of XpC sequences of the non-coding strand). Lower levels of termination occurred 
with adriamycin, and these were also ne nucleotide prior to G residues of the coding strand, but with greater sequence 
specificity since they were observed mainly at G of GpC sequences of the non-coding strand. The same sites were also 
observed with adriamycin i  the absence of reducing conditions and the level of termination atthese sites was enhanced 
up to 10-fold by Fez ÷ and Fe z÷, but not by Cu 2÷, Zn 2÷, Co 2+ or Ni 2÷. These results suggest that an iron-adriamycin 
complex with DNA is highly sequence-specific and results in adducts, similar to those of mitomycin C, which can termi- 
nate the transcription process. Such a mechanism offers new insights into the possible mode of action of anthracyclines. 
Adriamycin; Mitomycin C; DNA adduct; Xanthine oxidase; Sequence specificity; Divalent metal ion 
1. INTRODUCTION 
Adriamycin has been in routine clinical use as an 
anticancer agent for two decades [1-3]. Full 
realisation of its antineoplastic potential is limited 
by an associated cardiotoxicity [4,5] and there have 
been extensive efforts to develop more active 
and/or less cardiotoxic derivatives to combat his 
problem [6,7]. In order to place the development 
of new derivatives of these anthracyclines 
(adriamycin and daunomycin) on a more rational 
basis, there have been widespread and concerted 
efforts to delineate the mode of action of these 
drugs. Although membrane binding [8] and im- 
pairment of topoisomerase II activity [9] are possi- 
ble modes of action, there is an emerging body of 
evidence to show that the biological activity of 
these drugs correlates with DNA binding [10] or 
with a range of DNA-related events [2,11]. 
The role of DNA as an important receptor for 
anthracyclines may involve the formation of 
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covalent adducts with DNA, and such adducts 
have been well documented by chemical and en- 
zymic reduction in vitro [12-14]. If these adducts 
occur to a significant degree in vivo, then it is ex- 
pected that they would result in termination of 
transcription, and may therefore comprise an im- 
portant mode of action of these drugs, particularly 
in the light that tumour ceils contain a more reduc- 
ing environment than normal cells [15]. Similar ad- 
ducts with mitomycin C have been well 
documented [16-18]. We present here an in vitro 
transcription assay which exhibits blockage of 
transcription by E. coli RNA polymerase at 
specific DNA sites when mitomycin C is reduced 
by xanthine oxidase/NADH, or when adriamycin 
is present with Fe 2÷ or Fe 3+. 
2. EXPERIMENTAL 
2.1. Reagents 
Adriamycin was a gift from Farmitalia Carlo Erba (Milan). 
Mitomycin C was obtained from Sigma. Xanthine oxidase was 
supplied by Dr A. Wedd (La Trobe University). 
2.2. Transcription 
A 497-bp PuvlI/SalI restriction fragment of a modified 
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Fig. 1. Autoradiogram of RNA transcripts detected following elongation (5rain) of the initiated complex treated with 1 mM mitomycin 
C (MC) or adriamycin (AD) 15 min, 30 rain, 1, 2 or 4 h (denoted 15, 30, 1, 2 and 4, respectively) at 37°C, and also under educing 
conditions in the presence of xanthine oxidase (XO) and NADH. The initiated complex is shown in lane I, and the resulting transcript 
after 5 rain of elongation in lane E. Sequence lanes are denoted as C (termination by methoxy-CTP) and G (termination by 
methoxy-GTP). 
pBR322 vector contained the lac UV5 promoter and was uti- 
lized for in vitro transcription with E. coli RNA polymerase 
[19]. Transcription was initiated to form a stable ternary com- 
plex as in [19,20]. Adriamycin was added to defined concentra- 
tions. Metal ions were then added to a concentration f 150/~M 
while the reducing system was formed by the addition of 
NADH (2 raM) and 1.5 U xanthine oxidase [21]. The reaction 
mixtures were incubated at 37°C for various times before the 
transcript was elongated and then terminated as described 
[19,201. 
2.3. Electrophoresis and autoradiography 
Electrophoresis, autoradiography and densitometric analysis 
were performed using the techniques in [19,20]. 
3. RESULTS 
0 m 05  
The effect o f  the xanthine ox idase /NADH 
reducing system on mitomycin C and adr iamycin is 
shown in fig. 1. Minimal  pausing is evident in the 
control  e longat ion lane compared  to the amount  of  
ful l- length transcr ipt.  An  extensive amount  o f  
specific b lockage was obta ined with mitomycin C 
under reducing condit ions,  while the non-reducing 
control  lanes show essential ly only background 
pausing. A quantitat ive analysis o f  the sequence 
specif icity of  mitomycin C is presented in fig.2. 
In contrast,  adr iamycin alone resulted in many 
blocked transcripts after 15 min react ion time, and 
a low level of  full- length transcript which de- 
creased further with react ion time (f ig. l ) .  The 
blockages observed under non-reducing condit ions 
are essentially the same when in the presence of  
xanthine ox idase /NADH,  and some addit ional  
bands are also evident (e.g. between RNA lengths 
of  80 and 109). The enhanced intensity of  those 
bands under reducing condit ions is due largely to 
a greater stabi l i ty of  the ternary complex under 
these condit ions,  and this was conf i rmed by 
separate xperiments in which the addi t ion of  xan- 
thine ox idase /NADH (but not with either agent 
alone) produced much higher yields o f  full- length 
transcr ipt  (not shown). This effect probab ly  relates 
to a destabi l isat ion of  the ternary complex by 
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Fig.2. Mitomycin C transcriptional blockage sites induced by reductive activation. The mole fraction of RNA transcripts is shown (2 h 
incubation lane of fig.l), together with the sequence of the DNA non-coding strand, numbered from G of the initiating GpA 
dinucleotide. High-occupancy sites (>0.25% mole fraction of RNA) have been defined by a dashed line. 
235 
Volume 246, number 1,2 FEBS LETTERS 
ELONG lAD - I hq tAD- 2hr! A D-4h r I 
C G i I 5 15 I 5 15 G C 1 5 15 1 5 15 I C G 
March 1989 
l o9 -  ~ ........ ~ , ; :~  
w 
80-w 
53~ 
m 
2 8 1 m  
b 
P~ 
I 
m 
m 
236 
Volume 246, number 1,2 FEBS LETTERS March 1989 
Fig.3. Autoradiogram of adriamycin-induced transcriptional blockage sites following 1, 5 and 15 min of elongation after 1, 2 or 4 h 
of exposure of the initiated complex to adriamycin (50 ,aM) at 37°C. The initiated complex is shown in lane C and methoxy-CTP and 
methoxy-GTP sequencing lanes in C and G. 
adriamycin, but was diminished when the drug was 
bound to the xanthine oxidase-NADH complex. 
In the absence of  reducing conditions the forma- 
tion of  adriamycin block sites increased slowly 
with time over 4 h (fig.3). There was no evidence 
of  elongation past most of  these sites over 15 rain 
(fig.3) and this demonstrates that the drug associa- 
tion at these sites is much more permanent han for 
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Fig.4. Autoradiogram of adriamycin (50,aM) induced transcriptional blockage sites after treatment of he initiated complex for 0.5, 
2 or 4 h at 37°C in the presence of divalent metal ions (150 ,aM) or desferrioxamine (DES) at 15 or 150 aM. The ternary transcription 
complexes were elongated for 2 min for all samples. 
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Fig.5. Adriamycin-induced transcriptional blockage sites under no -r ductive conditions. The mole fraction of each transcript is shown 
after 4 h of exposure of the initiated complex to adriamycin, and subsequently 15 minof elongation (fig.3). The mole fraction of 
transcript has been corrected to allow statistically for undetected adducts downstream f existing blocked sites [31]. High-occupancy 
sites (mole fraction > 2%) have been defined by a dashed line. 
reversibly bound adriamycin which dissociates 
rapidly from DNA and is not detected by the 
transcription assay at 37°C, but can be seen at 
10 ° C [221. 
Since apparent adducts of adriamycin were 
observed under non-reducing conditions, one 
possibility was that these adducts derived from 
reduction via thiol groups (e.g. serum albumin) as 
suggested by Favandon [23], with the electron flow 
mediated by Fe 2+ [24]. For this reason we examin- 
ed the dependence of the apparent adducts on the 
presence of Fe 2+. During this process we establish- 
ed that both Fe z+ and Fe 3+ enhanced the forma- 
tion of transcriptional blockages. A further 
examination of the metal ion dependence has now 
shown that the termination of transcription is 
metal-ion-dependent, with only Fe 2+ and Fe ~+ 
resulting in enhanced sequence specific termina- 
tion of transcription (fig.4). A quantitative 
analysis of the sequence specificity of adriamycin 
is shown in fig.5. 
4. DISCUSSION 
4.1. Mitomycin C 
The transcriptional blockages observed follow- 
ing reductive activation of mitomycin C confirm 
the well-documented observation of' DNA adducts 
with this compound [16-18]. The fact that hese 
blockages are independent of elongation time is 
consistent with such covalent adducts. The se- 
quence specificity shows that blockages occur at X 
of XpC sequences and this suggests that adducts 
are exclusively on the G residue of the coding 
strand, since drug-induced transcriptional 
blockages have routinely been detected immediate- 
ly adjacent o drug sites [19,20]. All of the 21 high- 
occupancy blockage sites in the transcribed se- 
quence occur at X of XpC sequences and confirms 
the previous observations of G-specific adducts 
(non-coding strand) with mitomycin C. Adducts 
on the non-coding strand were apparently not 
detected and this is consistent with previous obser- 
vations with psoralen adducts [25]. 
4.2. Adriamycin 
Reductive activation of adriamycin did not yield 
any transcriptional blockages in addition to those 
observed under non-reducing conditions, even 
though the adriamycin was clearly being reduced, 
as shown by an increasing amount of 
adriamycinone precipitating from the reaction 
[26]. The reason that adducts previously observed 
by others under reducing conditions [12,13] were 
not observed in the transcriptional analysis is 
presumably due to the 1000-fold lower DNA con- 
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centration employed in the present work which is 
based on nanomolar levels of promoter-containing 
DNA fragments. The implications then are that 
reduced adriamycin species are considerably less 
reactive than the corresponding mitomycin C reac- 
tants and that the gradual development of blocked 
transcripts of adriamycin under reducing condi- 
tions is only a background effect, identical to that 
observed in the absence of a reducing en- 
vironment. 
A much more fundamental question which must 
be addressed is the nature of termination of 
transcription induced by adriamycin under non- 
reducing conditions. This phenomenon is drug- 
dependent and also specific for FeE+/Fe 2+, sug- 
gesting a DNA-adriamycin-Fe complex. Since this 
complex is independent of elongation time, it has 
the characteristics of a covalent adduct, but could 
in principle also be d scribed as a long-lived rever- 
sible complex. Irrespective of the exact nature of 
the complex, the net effect of virtually abolishing 
the transcription process is dramatic. The DNA se- 
quence specificity of these adducts was GpC (non- 
coding strand) with blockage at the G residue being 
due to an adduct or complex on G of the coding 
strand. All seven GpC sequences in the transcribed 
region are associated with a blockage at the G site, 
and 5 of the 6 highest occupancy sites are at GpC 
sequences (fig.5). By analogy with the XpC site 
associated with mitomycin C, adriamycin shows a 
greater degree of specificity, and implies that both 
of the (G. C) base-pairs are involved in the binding 
site. This may relate to the conformation of DNA 
around GpC sites which are known to have a 
smaller distance between the two guanines, viz. 
6.5 ,~, compared to 9.1 ,~ in CpG sequences [27]. 
The lack of effect of desferrioxamine (fig.4) may 
be due to the fact that the iron may not be accessi- 
ble to this complexing agent when bound to drug 
and/or DNA. 
The 1:3 complex of iron and adriamycin is a 
stable compound [28,29] with high affinity for 
DNA. It is therefore probable that the ternary 
DNA-adriamycin-Fe complex involves uch a com- 
pound with the specificity derived from (G.C) 
contacts with both drug and iron moieties of the 
complex. 
4.3. Pharmacological implications 
Any process that results in the complete termina- 
tion of transcription in vitro, as distinct from 
merely a delay, as in the case of reversibly binding 
drugs, must be considered as an important poten- 
tial mode of action in vivo. The mechanism of ac- 
tion of the anthracyclines has been investigated for 
two decades, and to the many probable contenders 
should now be added the possibility of a drug- 
Fe2+/Fe3+-mediated rmination of transcription. 
If this proves to be a major mode of action, the 
selectivity for tumour tissues may well be 
associated with the GpC specificity of the ternary 
complex possibly affecting the B-Z transition of 
(GC)n sequences which are thought to act as 
regulatory elements in eukaryotes [30]. 
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